Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30


Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.

Karlsson T, Krakstad C, Tangen IL, Hoivik EA, Pollock PM, Salvesen HB, Lewis AE.

Oncotarget. 2017 Jan 17;8(3):3881-3894. doi: 10.18632/oncotarget.13989.


E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing.

Millán-Uclés Á, Zuluaga S, Marqués M, Vallejo-Díaz J, Sanz L, Cariaga-Martínez AE, Real FX, Carrera AC.

Oncotarget. 2016 Dec 20;7(51):84054-84071. doi: 10.18632/oncotarget.13414.



Anwer MS.

J Biosci (Rajshari). 2012;20:1-23.


PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.

Li B, Sun A, Jiang W, Thrasher JB, Terranova P.

Am J Clin Exp Urol. 2014 Oct 2;2(3):188-98. eCollection 2014. Review.


Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts.

Falasca M, Maffucci T.

Front Physiol. 2014 Oct 15;5:391. doi: 10.3389/fphys.2014.00391. eCollection 2014. Review.


Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.

Akinleye A, Avvaru P, Furqan M, Song Y, Liu D.

J Hematol Oncol. 2013 Nov 22;6(1):88. doi: 10.1186/1756-8722-6-88. Review.


Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines.

Juvin V, Malek M, Anderson KE, Dion C, Chessa T, Lecureuil C, Ferguson GJ, Cosulich S, Hawkins PT, Stephens LR.

PLoS One. 2013 Oct 4;8(10):e75045. doi: 10.1371/journal.pone.0075045. eCollection 2013.


Characterization of a tumor-associated activating mutation of the p110β PI 3-kinase.

Dbouk HA, Khalil BD, Wu H, Shymanets A, Nürnberg B, Backer JM.

PLoS One. 2013 May 29;8(5):e63833. doi: 10.1371/journal.pone.0063833. Print 2013.


Targeting the PI3K pathway for cancer therapy.

Sadeghi N, Gerber DE.

Future Med Chem. 2012 Jun;4(9):1153-69. doi: 10.4155/fmc.12.56. Review.


Integrin/Fak/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes.

Beauséjour M, Noël D, Thibodeau S, Bouchard V, Harnois C, Beaulieu JF, Demers MJ, Vachon PH.

Apoptosis. 2012 Jun;17(6):566-78. doi: 10.1007/s10495-012-0713-6.


Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells.

Müller KM, Tveteraas IH, Aasrum M, Ødegård J, Dawood M, Dajani O, Christoffersen T, Sandnes DL.

BMC Cancer. 2011 Oct 2;11:421. doi: 10.1186/1471-2407-11-421.


A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.

Dbouk HA, Pang H, Fiser A, Backer JM.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19897-902. doi: 10.1073/pnas.1008739107. Epub 2010 Oct 28.


The p110α and p110β isoforms of class I phosphatidylinositol 3-kinase are involved in toll-like receptor 5 signaling in epithelial cells.

Ivison SM, Khan MA, Graham NR, Shobab LA, Yao Y, Kifayet A, Sly LM, Steiner TS.

Mediators Inflamm. 2010;2010. pii: 652098. doi: 10.1155/2010/652098. Epub 2010 Oct 3.


Phosphatidylinositol-3-kinase p110γ contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells.

Hohenester S, Gates A, Wimmer R, Beuers U, Anwer MS, Rust C, Webster CR.

J Hepatol. 2010 Nov;53(5):918-26. doi: 10.1016/j.jhep.2010.05.015. Epub 2010 Jul 17.


Phosphatidylinositol 3-kinase: the oncoprotein.

Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A.

Curr Top Microbiol Immunol. 2010;347:79-104. doi: 10.1007/82_2010_80. Review.


Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu X.

Carcinogenesis. 2010 Aug;31(8):1387-91. doi: 10.1093/carcin/bgq110. Epub 2010 Jun 7.


Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3-kinase inhibition in the human cervical cancer cell-line.

Park JK, Cho CH, Ramachandran S, Shin SJ, Kwon SH, Kwon SY, Cha SD.

Cancer Res Treat. 2006 Apr;38(2):112-7. doi: 10.4143/crt.2006.38.2.112. Epub 2006 Apr 30.


Targeting the phosphoinositide 3-kinase pathway in cancer.

Liu P, Cheng H, Roberts TM, Zhao JJ.

Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926. Review.

Supplemental Content

Support Center